These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 25598292)
1. Enalapril treatment increases T cell number and promotes polarization towards M1-like macrophages locally in diabetic nephropathy. Cucak H; Nielsen Fink L; Højgaard Pedersen M; Rosendahl A Int Immunopharmacol; 2015 Mar; 25(1):30-42. PubMed ID: 25598292 [TBL] [Abstract][Full Text] [Related]
2. Renoprotective effects of combination of angiotensin converting enzyme inhibitor with mycophenolate mofetil in diabetic rats. Wu YG; Lin H; Qian H; Zhao M; Qi XM; Wu GZ; Lin ST Inflamm Res; 2006 May; 55(5):192-9. PubMed ID: 16830106 [TBL] [Abstract][Full Text] [Related]
3. Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice. Zheng F; Zeng YJ; Plati AR; Elliot SJ; Berho M; Potier M; Striker LJ; Striker GE Kidney Int; 2006 Aug; 70(3):507-14. PubMed ID: 16775596 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of T-cell activation by the CTLA4-Fc Abatacept is sufficient to ameliorate proteinuric kidney disease. Herrera M; Söderberg M; Sabirsh A; Valastro B; Mölne J; Santamaria B; Valverde AM; Guionaud S; Heasman S; Bigley A; Jermutus L; Rondinone C; Coghlan M; Baker D; Quinn CM Am J Physiol Renal Physiol; 2017 Apr; 312(4):F748-F759. PubMed ID: 27440778 [TBL] [Abstract][Full Text] [Related]
5. An additive effect of anti-PAI-1 antibody to ACE inhibitor on slowing the progression of diabetic kidney disease. Gu C; Zhang J; Noble NA; Peng XR; Huang Y Am J Physiol Renal Physiol; 2016 Nov; 311(5):F852-F863. PubMed ID: 27511457 [TBL] [Abstract][Full Text] [Related]
6. Possible role of VEGF in the progression of kidney disease in streptozotocin (STZ)-induced diabetic rats: effects of an ACE inhibitor and an angiotensin II receptor antagonist. Kakizawa H; Itoh Y; Imamura S; Matsumoto T; Ishiwata Y; Ono Y; Yamamoto K; Kato T; Hayakawa N; Oda N; Goto Y; Goto Y; Nagasaka A; Senda T; Itoh M Horm Metab Res; 2004 Jul; 36(7):458-64. PubMed ID: 15305228 [TBL] [Abstract][Full Text] [Related]
7. Nephropathy in model combining genetic hypertension with experimental diabetes. Enalapril versus hydralazine and metoprolol therapy. Cooper ME; Allen TJ; O'Brien RC; Papazoglou D; Clarke BE; Jerums G; Doyle AE Diabetes; 1990 Dec; 39(12):1575-9. PubMed ID: 2245881 [TBL] [Abstract][Full Text] [Related]
8. Meprin-alpha in chronic diabetic nephropathy: interaction with the renin-angiotensin axis. Mathew R; Futterweit S; Valderrama E; Tarectecan AA; Bylander JE; Bond JS; Trachtman H Am J Physiol Renal Physiol; 2005 Oct; 289(4):F911-21. PubMed ID: 15942051 [TBL] [Abstract][Full Text] [Related]
9. Hyperoside Suppresses Renal Inflammation by Regulating Macrophage Polarization in Mice With Type 2 Diabetes Mellitus. Liu J; Zhang Y; Sheng H; Liang C; Liu H; Moran Guerrero JA; Lu Z; Mao W; Dai Z; Liu X; Zhang L Front Immunol; 2021; 12():733808. PubMed ID: 34925317 [TBL] [Abstract][Full Text] [Related]
10. Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats. Kang YS; Ko GJ; Lee MH; Song HK; Han SY; Han KH; Kim HK; Han JY; Cha DR Nephrol Dial Transplant; 2009 Jan; 24(1):73-84. PubMed ID: 18682491 [TBL] [Abstract][Full Text] [Related]
11. Superior renoprotective effects of the combination of breviscapine with enalapril and its mechanism in diabetic rats. Xu XX; Zhang W; Zhang P; Qi XM; Wu YG; Shen JJ Phytomedicine; 2013 Jul; 20(10):820-7. PubMed ID: 23664882 [TBL] [Abstract][Full Text] [Related]
12. Macrophage Cyclooxygenase-2 Protects Against Development of Diabetic Nephropathy. Wang X; Yao B; Wang Y; Fan X; Wang S; Niu A; Yang H; Fogo A; Zhang MZ; Harris RC Diabetes; 2017 Feb; 66(2):494-504. PubMed ID: 27815317 [TBL] [Abstract][Full Text] [Related]
13. Effects of long-term enalapril treatment on persistent microalbuminuria in normotensive type 2 diabetic patients: results of a 4-year, prospective, randomized study. Sano T; Hotta N; Kawamura T; Matsumae H; Chaya S; Sasaki H; Nakayama M; Hara T; Matsuo S; Sakamoto N Diabet Med; 1996 Feb; 13(2):120-4. PubMed ID: 8641115 [TBL] [Abstract][Full Text] [Related]
14. Nilvadipine attenuates mesangial expansion and glomerular hypertrophy in diabetic db/db mice, a model for type 2 diabetes. Moriyama T; Oka K; Ueda H; Imai E Clin Exp Nephrol; 2004 Sep; 8(3):230-6. PubMed ID: 15480900 [TBL] [Abstract][Full Text] [Related]
15. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Chow F; Ozols E; Nikolic-Paterson DJ; Atkins RC; Tesch GH Kidney Int; 2004 Jan; 65(1):116-28. PubMed ID: 14675042 [TBL] [Abstract][Full Text] [Related]
17. Mycophenolate Mofetil Ameliorates Diabetic Nephropathy in db/db Mice. Seo JW; Kim YG; Lee SH; Lee A; Kim DJ; Jeong KH; Lee KH; Hwang SJ; Woo JS; Lim SJ; Kim W; Moon JY Biomed Res Int; 2015; 2015():301627. PubMed ID: 26345532 [TBL] [Abstract][Full Text] [Related]
18. Renoprotective effects of valsartan and enalapril in STZ-induced diabetes in rats. Kalender B; Oztürk M; Tunçdemir M; Uysal O; Dagistanli FK; Yegenaga I; Erek E Acta Histochem; 2002; 104(2):123-30. PubMed ID: 12086332 [TBL] [Abstract][Full Text] [Related]
19. Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats. Bilan VP; Salah EM; Bastacky S; Jones HB; Mayers RM; Zinker B; Poucher SM; Tofovic SP J Endocrinol; 2011 Sep; 210(3):293-308. PubMed ID: 21680617 [TBL] [Abstract][Full Text] [Related]
20. Losartan ameliorates progression of glomerular structural changes in diabetic KKAy mice. Sasaki M; Uehara S; Ohta H; Taguchi K; Kemi M; Nishikibe M; Matsumoto H Life Sci; 2004 Jul; 75(7):869-80. PubMed ID: 15183078 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]